Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company’s products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
| Business Activity | PASS |
| Debt Ratio (0.33%) | PASS |
| Cash Ratio (0.00%) | PASS |
| Receivables Ratio (0.10%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | PASS |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-08-06 | 2.01 | Pending | — |
| 2026-04-28 | 1.86 | 2.09 | +12.2% |
| 2026-02-10 | 2.40 | 2.42 | +0.9% |
| 2025-11-05 | 1.87 | 1.90 | +1.8% |
| 2025-08-07 | 1.18 | 0.77 | -34.7% |
| 2025-05-05 | 0.87 | 0.91 | +4.2% |
| 2025-02-06 | 2.29 | 2.31 | +0.8% |
| 2024-10-30 | 1.74 | 1.74 | +0.2% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2.1B | $238.1M | $640.1M | $1.5B | $395.1M | 1.22 |
| 2025-12-31 | $2.2B | $139.3M | $453.9M | $1.5B | $282.6M | — |
| 2025-09-30 | $2.0B | $230.9M | $638.2M | $1.4B | $338.3M | 1.17 |
| 2025-06-30 | $2.1B | $152.8M | $575.7M | $1.5B | $396.4M | 0.77 |
| 2025-03-31 | $1.9B | $182.0M | $549.6M | $1.4B | $338.9M | 0.92 |
| 2024-12-31 | — | — | — | — | — | 1.20 |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2026-04-01 | NOOR JEHANZEB | Officer | 6,626 | — |
| 2026-03-12 | WINKLER LORI | Officer | 2,650 | $250.8K |
| 2026-03-06 | UPADHYAY SUKETU P | Chief Financial Officer | 14,776 | — |
| 2026-03-06 | PHIPPS CHAD F | Officer | 6,786 | — |
| 2026-03-06 | WINKLER LORI | Officer | 5,634 | — |
| 2026-03-06 | VAN ZUILEN WILFRED | Officer | 7,004 | — |
| 2026-03-06 | YI SANG | Officer | 9,414 | — |
| 2026-03-06 | STELLATO PAUL A | Officer | 1,970 | — |
| 2026-03-06 | TORNOS IVAN | Chief Executive Officer | 34,704 | — |
| 2026-02-25 | UPADHYAY SUKETU P | Chief Financial Officer | 6,364 | — |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Dodge & Cox Inc. | 23.5M | $2.0B | 0.1% |
| Blackrock Inc. | 15.3M | $1.3B | 0.1% |
| Harris Associates L.P. | 13.0M | $1.1B | 0.1% |
| Vanguard Capital Management LLC | 12.8M | $1.1B | 0.1% |
| Capital International Investors | 9.1M | $779.7M | 0.0% |
| State Street Corporation | 8.8M | $754.5M | 0.0% |
| Vanguard Portfolio Management LLC | 8.7M | $739.6M | 0.0% |
| Price (T.Rowe) Associates Inc | 8.0M | $684.0M | 0.0% |
| Franklin Resources, Inc. | 5.5M | $466.2M | 0.0% |
| Geode Capital Management, LLC | 5.4M | $459.9M | 0.0% |
Buy
Hold
Sell
Strong Sell
$23.7B
1.30
0.473
21
$8.4B
$7.6B
+34.1%
1.2%
2.59
3.97
0.1%
17,000
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-08-06 | $2.01 | Pending | — |
| 2026-04-28 | $1.86 | $2.09 | +12.2% |
| 2026-02-10 | $2.40 | $2.42 | +0.9% |
| 2025-11-05 | $1.87 | $1.90 | +1.8% |
| 2025-08-07 | $1.18 | $0.77 | -34.7% |
| 2025-05-05 | $0.87 | $0.91 | +4.2% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($98.52, 21 analysts) | |||
| 10 | $833.40 | +$151.80 (18%) | 1.2R |
| 50 | $4,167.00 | +$759.00 (18%) | 1.2R |
| 100 | $8,334.00 | +$1,518.00 (18%) | 1.2R |
| To Fair Value ($107.91) | |||
| 10 | $833.40 | +$245.70 (29%) | 2.0R |
| 50 | $4,167.00 | +$1,228.50 (29%) | 2.0R |
| 100 | $8,334.00 | +$2,457.00 (29%) | 2.0R |
- Elevated short interest (3.97 days to cover)
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| BDX | 0.444 |
| ENOV | 0.437 |
| TREX | 0.419 |
| MDT | 0.410 |
| SYK | 0.409 |
| Ticker | Correlation |
|---|---|
| LPTVQ | -0.328 |
| 4140.SR | -0.166 |
| BEYOUT.KW | -0.154 |
| ARGAN.KW | -0.142 |
| OSOUL.KW | -0.140 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker’s recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.
Related Tickers
Similar in Healthcare
Also in TE500